• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

将成本效益纳入新药许可要求：第四个障碍。

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.

作者信息

Taylor R S, Drummond M F, Salkeld G, Sullivan S D

机构信息

Department of Public Health and Epidemiology, University of Birmingham, Birmingham B15 2TT.

出版信息

BMJ. 2004 Oct 23;329(7472):972-5. doi: 10.1136/bmj.329.7472.972.

DOI:10.1136/bmj.329.7472.972
PMID:15499118
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC524116/
Abstract

Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?

摘要

越来越多的国家在决定哪些药物可供处方使用时会考虑成本效益。不同的方法是如何运作的，现在是进行标准化的时候了吗？

相似文献

1
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.将成本效益纳入新药许可要求：第四个障碍。
BMJ. 2004 Oct 23;329(7472):972-5. doi: 10.1136/bmj.329.7472.972.
2
Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.国际药品支出控制经验教训。三：规范行业。
BMJ. 1996 Jul 6;313(7048):33-5. doi: 10.1136/bmj.313.7048.33.
3
The use of health economic information by reimbursement authorities.报销机构对卫生经济信息的使用。
Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii60-3. doi: 10.1093/rheumatology/keg499.
4
Legislation would put drugs and other therapies to a useful test.
Manag Care. 2008 May;17(5):12-3.
5
Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.与美国的实践相比，欧洲的循证审查似乎导致了一些药物价格的降低。
Health Aff (Millwood). 2013 Apr;32(4):762-70. doi: 10.1377/hlthaff.2012.0707.
6
[Orphan drugs: drugs for rare diseases].[孤儿药：用于罕见病的药物]
Dtsch Med Wochenschr. 2010 May;135(18):p17.
7
Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare.药物基因组学在药物许可和医疗保健方面的经济与监管考量
Nat Biotechnol. 2003 Jul;21(7):747-53. doi: 10.1038/nbt0703-747.
8
Generic drugs: the stalling game.仿制药：停滞不前的局面。
Consum Rep. 2001 Jul;66(7):36-40.
9
New law to improve animal drug review.改善动物药品审评的新法律。
FDA Consum. 2004 Jan-Feb;38(1):5.
10
The costs and benefits of regulations for reimbursement of new drugs.新药报销规定的成本与效益。
Health Policy. 2006 Dec;79(2-3):337-44. doi: 10.1016/j.healthpol.2006.02.004. Epub 2006 Mar 20.

引用本文的文献

1
Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia.解析基于模型的经济分析中的不确定性与澳大利亚药品资助建议之间的关联。
Pharmacoeconomics. 2025 Mar;43(3):283-296. doi: 10.1007/s40273-024-01446-z. Epub 2024 Nov 15.
2
Health technology assessment in mental health services.心理健康服务中的卫生技术评估。
Ind Psychiatry J. 2024 Aug;33(Suppl 1):S246-S249. doi: 10.4103/ipj.ipj_155_24. Epub 2024 Aug 27.
3
Essential medicines concept and health technology assessment approaches to prioritising medicines: selection versus incorporation.基本药物概念与药物优先排序的卫生技术评估方法：选择与纳入
J Pharm Policy Pract. 2023 Jul 13;16(1):88. doi: 10.1186/s40545-023-00595-4.
4
[The molecular tumor board].[分子肿瘤学专家组]
Chirurg. 2021 Nov;92(11):1011-1015. doi: 10.1007/s00104-021-01487-6.
5
Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials.国家癌症研究所资助的网络癌症临床试验中的经济评估。
Value Health. 2020 Dec;23(12):1653-1661. doi: 10.1016/j.jval.2020.08.2095. Epub 2020 Oct 9.
6
Willingness to pay for one quality-adjusted life year in Iran.伊朗对一个质量调整生命年的支付意愿。
Cost Eff Resour Alloc. 2019 Feb 28;17:4. doi: 10.1186/s12962-019-0172-9. eCollection 2019.
7
The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method.糖尿病患者中质量调整生命年的价值：一项使用支付意愿法的调查研究。
Pharmacoecon Open. 2019 Sep;3(3):311-319. doi: 10.1007/s41669-018-0111-2.
8
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.欧盟的风险分担协议：主要趋势的系统综述
Pharmacoecon Open. 2018 Jun;2(2):109-123. doi: 10.1007/s41669-017-0044-1.
9
Sustainability of Endovenous Iron Deficiency Anaemia Treatment: Hospital-Based Health Technology Assessment in IBD Patients.静脉补铁治疗缺铁性贫血的可持续性：基于医院的炎症性肠病患者健康技术评估
Biomed Res Int. 2017;2017:3470893. doi: 10.1155/2017/3470893. Epub 2017 Jul 6.
10
Patients' Preferences for Outcome, Process and Cost Attributes in Cancer Treatment: A Systematic Review of Discrete Choice Experiments.患者对癌症治疗结局、过程和成本属性的偏好：离散选择实验的系统评价。
Patient. 2017 Oct;10(5):553-565. doi: 10.1007/s40271-017-0235-y.

本文引用的文献

1
Should commercial-in-confidence data be used by decision makers when making assessments of cost-effectiveness?
Appl Health Econ Health Policy. 2002;1(2):53-4.
2
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.制药行业赞助与研究结果及质量：系统评价
BMJ. 2003 May 31;326(7400):1167-70. doi: 10.1136/bmj.326.7400.1167.
3
Reforming pharmaceutical policies in the European Union: a "penguin effect"?欧盟药品政策改革：“企鹅效应”？
Int J Health Serv. 2003;33(1):1-28. doi: 10.2190/1JC6-FRL4-QM2L-QN6E.
4
Health economic evaluation in Japan: a case study of one aspect of health technology assessment.
Health Policy. 2003 Feb;63(2):197-204. doi: 10.1016/s0168-8510(02)00066-0.
5
After Nice: where now for health policy in the European Union?继尼斯会议之后：欧盟卫生政策的未来走向何方？
J R Soc Med. 2003 Jan;96(1):1-2. doi: 10.1258/jrsm.96.1.1.
6
Is the NICE process flawed?
Lancet. 2002 Jun 15;359(9323):2120. doi: 10.1016/S0140-6736(02)08933-X.
7
Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).成本效益分析与决策的一致性：来自澳大利亚药品报销的证据（1991年至1996年）
Pharmacoeconomics. 2001;19(11):1103-9. doi: 10.2165/00019053-200119110-00004.
8
NICE: faster access to modern treatments? Analysis of guidance on health technologies.英国国家卫生与临床优化研究所（NICE）：更快获得现代治疗方法？对卫生技术指南的分析
BMJ. 2001 Dec 1;323(7324):1300-3. doi: 10.1136/bmj.323.7324.1300.
9
Health economic guidelines--similarities, differences and some implications.卫生经济指南——异同点及一些启示
Value Health. 2001 May-Jun;4(3):225-50. doi: 10.1046/j.1524-4733.2001.43040.x.
10
Theory versus practice: a review of 'willingness-to-pay' in health and health care.理论与实践：对健康及医疗保健领域“支付意愿”的综述
Health Econ. 2001 Jan;10(1):39-52. doi: 10.1002/1099-1050(200101)10:1<39::aid-hec563>3.0.co;2-e.